Scientists probe tumor immune cells in bone cancer patients treated with mifamurtide
NCT ID NCT03737435
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examined stored tumor samples from 80 people with localized osteosarcoma who received chemotherapy with or without the drug mifamurtide. Researchers analyzed the immune cells and genes inside the tumors to see how the tumor environment relates to patient survival. The goal is to better understand why some patients respond better to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mifamurtide
What this could lead to
If successful, this could help doctors understand which patients with osteosarcoma might benefit most from adding mifamurtide to chemotherapy.
What could go wrong
This is a retrospective biological study, not a treatment trial. It only looks at stored tumor samples, so it cannot prove that mifamurtide works better or causes harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SSD Chemioterapia dei tumori dell'apparato locomotore
Bologna, 40136, Italy